Rigel Pharmaceuticals, Inc.
RIGL
$32.13
$2.769.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 299.50M | 294.02M | 282.08M | 267.92M | 203.08M |
| Total Other Revenue | 265.00K | 265.00K | -- | -- | -- |
| Total Revenue | 299.77M | 294.28M | 282.08M | 267.92M | 203.08M |
| Cost of Revenue | 56.35M | 52.92M | 47.70M | 49.80M | 46.82M |
| Gross Profit | 243.41M | 241.37M | 234.38M | 218.12M | 156.26M |
| SG&A Expenses | 118.84M | 115.90M | 115.43M | 113.54M | 112.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 175.19M | 168.82M | 163.13M | 163.33M | 159.15M |
| Operating Income | 124.58M | 125.47M | 118.95M | 104.59M | 43.93M |
| Income Before Tax | 121.97M | 121.83M | 114.34M | 99.14M | 38.12M |
| Income Tax Expenses | -242.26M | -245.20M | 1.04M | 1.32M | 946.00K |
| Earnings from Continuing Operations | 364.23 | 367.02 | 113.30 | 97.82 | 37.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 364.23M | 367.02M | 113.30M | 97.82M | 37.18M |
| EBIT | 124.58M | 125.47M | 118.95M | 104.59M | 43.93M |
| EBITDA | 126.99M | 127.88M | 121.37M | 107.01M | 46.36M |
| EPS Basic | 20.07 | 20.24 | 6.34 | 5.49 | 2.10 |
| Normalized Basic EPS | 4.23 | 4.24 | 4.00 | 3.48 | 1.35 |
| EPS Diluted | 18.73 | 18.92 | 6.17 | 5.41 | 2.07 |
| Normalized Diluted EPS | 4.05 | 4.08 | 3.89 | 3.43 | 1.33 |
| Average Basic Shares Outstanding | 72.54M | 71.94M | 71.38M | 70.94M | 70.60M |
| Average Diluted Shares Outstanding | 76.80M | 75.28M | 73.47M | 71.97M | 71.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |